Glycorex Transplantation (GTAB B) Stock Overview
A medical technology company, focuses on transplantation, blood transfusion, and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GTAB B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Glycorex Transplantation AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.23 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 0.94 |
| 1 Month Change | 7.21% |
| 3 Month Change | 9.31% |
| 1 Year Change | 94.76% |
| 3 Year Change | -63.80% |
| 5 Year Change | -86.96% |
| Change since IPO | -46.90% |
Recent News & Updates
Shareholder Returns
| GTAB B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 2.3% | -3.5% | -2.6% |
| 1Y | 94.8% | -9.6% | -4.1% |
Return vs Industry: GTAB B exceeded the Swedish Medical Equipment industry which returned -8.7% over the past year.
Return vs Market: GTAB B exceeded the Swedish Market which returned -3.1% over the past year.
Price Volatility
| GTAB B volatility | |
|---|---|
| GTAB B Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in SE Market | 13.5% |
| 10% least volatile stocks in SE Market | 4.1% |
Stable Share Price: GTAB B has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: GTAB B's weekly volatility has decreased from 17% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 20 | Johan Nilsson | www.glycorex.se |
Glycorex Transplantation AB (publ), a medical technology company, focuses on transplantation, blood transfusion, and autoimmune diseases. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company’s principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, liver, lung, and stem cell transplantation procedures.
Glycorex Transplantation AB (publ) Fundamentals Summary
| GTAB B fundamental statistics | |
|---|---|
| Market cap | SEK 181.36m |
| Earnings (TTM) | -SEK 9.08m |
| Revenue (TTM) | SEK 36.76m |
Is GTAB B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTAB B income statement (TTM) | |
|---|---|
| Revenue | SEK 36.76m |
| Cost of Revenue | SEK 7.03m |
| Gross Profit | SEK 29.74m |
| Other Expenses | SEK 38.82m |
| Earnings | -SEK 9.08m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 29, 2025
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 80.88% |
| Net Profit Margin | -24.70% |
| Debt/Equity Ratio | 0.5% |
How did GTAB B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/17 03:37 |
| End of Day Share Price | 2025/06/17 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Glycorex Transplantation AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.